Results 201 to 210 of about 2,303,005 (336)
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source
Linguistic bias and the hidden costs of science lost in translation. [PDF]
Reguera G.
europepmc +1 more source
Publishing Conference Proceedings and Events with DigitalCommons@WSU
J. Chris McGlone
openalex +1 more source
Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller +17 more
wiley +1 more source
Educational Association Children’s Library Publishing: the Case of Fairy Tales
Alexia Orfanou
openalex +1 more source
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad +35 more
wiley +1 more source
Predatory Publishing Awareness Among Dental Interns in Riyadh, Saudi Arabia: A Cross-Sectional Study. [PDF]
Alkadi L +4 more
europepmc +1 more source
Publishing a well‐established international environmental journal in Chinese [PDF]
Élisabeth Kessler, Keyu Zhang
openalex +1 more source

